Thank you for joining our conference call to discuss Amicus Therapeutics' second quarter 2020 financial results and corporate highlights. Speaking on today's call, we have John Crowley, Chairman and Chief Executive Officer; Bradley Campbell, President and Chief Operating Officer; Daphne Quimi, Chief Financial Officer; and Dr. Jeff Castelli, Chief Development Officer.
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 23.08% and -0.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Amicus Therapeutics (NASDAQ:FOLD) rose 0.6% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share increased 44.44% year over year to ($0.20), which beat the estimate of ($0.26).Revenue of $62,353,000 rose by 41.29% from the same period last year, which missed the estimate of $62,380,000.Outlook The upcoming fiscal year's revenue expected to be between $250,000,000 and $260,000,000.Conference Call Details Date: Aug 10, 2020Time: 08:30 AMView more earnings on FOLDET Webcast URL: https://edge.media-server.com/mmc/p/fvhk9nzfPrice Action Company's 52-week high was at $16.13Company's 52-week low was at $6.25Price action over last quarter: Up 32.05%Company Profile Amicus Therapeutics Inc is a biotechnology company. It is focused on discovering, developing, and delivering novel high-quality medicines for people living with rare metabolic diseases. Amicus Therapeutics is expanding a pipeline of medicines for rare metabolic diseases, including an industry- leading rare disease gene therapy portfolio.See more from Benzinga * Earnings Scheduled For August 10, 2020 * Stocks That Hit 52-Week Highs On Wednesday * Stocks That Hit 52-Week Highs On Monday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.